Gritstone, Gilead Partner To Develop Therapeutic HIV Vaccine
Deal Closely Follows COVID-19 Vaccine Effort
Gritstone will supply the same type of prime-boost vaccine technology it is applying to SARS-CoV-2, and Gilead will supply its own antigens, with the goal of curing HIV.
